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ABSTRACT
Monoclonal antibodies are important tools for cancer
therapy, however, three factors limit their effectiveness:
toxicity, poor tumor penetration, and inability to cross
the blood-brain barrier. This review discusses the
emerging ﬁeld of stem cell-mediated antibody delivery
and how this approach may improve antibody therapy
of cancer by overcoming these obstacles. STEM CELLS
2010;28:2084–2087
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INTRODUCTION
Recombinant monoclonal antibodies have emerged as impor-
tant tools for cancer therapy. Despite the therapeutic advan-
tages conferred by antibodies, three major weaknesses limit
their effectiveness, that is, (a) poor penetration of solid
tumors, (b) inability to cross the blood-brain barrier (BBB),
and (c) mechanism-dependent and mechanism-independent
toxicities [1, 2]. Considerable research has focused on these
obstacles and several novel solutions have been proposed to
overcome them. However, no single solution has yet been
able to address all three weaknesses.
Current methods require repeated systemic delivery of
large quantities of antibodies to maintain therapeutic concen-
trations at tumor sites. However, an emerging strategy is the
use of stem cells for in vivo antibody production. The inher-
ent tumor-tropic properties of stem cells and their ability to
traverse the BBB can be harnessed for tumor-selective deliv-
ery of such therapeutic antibodies. Using this approach, cumu-
lative stem cell-mediated secretion of small quantities of anti-
bodies speciﬁcally at tumor sites would be expected to result
in therapeutically effective antibody concentrations. This
approach could simultaneously overcome all three limitations
of current antibody delivery methods and enhance therapeutic
efﬁcacy, while minimizing undesired exposure of healthy tis-
sue to antibodies, thereby reducing side effects such as car-
diac toxicity associated with the HER2/neu (human epidermal
growth factor receptor 2)-speciﬁc antibody trastuzumab (Her-
ceptin) (Genentech, South San Francisco, CA; http://www.her-
ceptin.com/index.jsp) in some patients [1].
Stem Cell Tropism to Tumors
Neural stem/progenitor cells (NSCs) and mesenchymal stem
cells (MSCs) are multipotent cells that have an inherent ability
to migrate to malignant tumor sites both within and outside of
the central nervous system. Therapeutic beneﬁt has been dem-
onstrated with various anticancer agents, including interleu-
kins, interferons, and prodrug-activating enzymes [3]. The mo-
lecular mediators of this tumor tropism include cytokines,
growth factors, extracellular matrix (ECM), and ECM-remodel-
ing proteins [4, 5]. Unlike systemically delivered drugs, NSCs
have been shown to inﬁltrate solid tumor parenchyma and also
localize to hypoxic regions of tumors [6]. This provides a dis-
tribution advantage over intravenously (i.v.) delivered antibod-
ies, which diffuse only in the immediate vicinity of blood ves-
sels. Additionally, NSCs and MSCs have the ability to traverse
the BBB to reach primary brain tumors or solid tumor metasta-
ses in the brain [3]. These advantageous properties suggest that
stem cell-mediated delivery of antibodies may enable distribu-
tion to sites that are not readily accessible by i.v. injected anti-
bodies and improve the effectiveness of cancer immunother-
apy. Recent research has begun to investigate the full potential
of using stem cells as a platform for antibody therapy.
Stem Cell-Mediated Antibody Delivery
Stem cells can be genetically modiﬁed by viral and nonviral
methods to express intact antibody or single-chain antibody
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Recently, it has been demonstrated that human NSCs can be
transduced with adenoviral or lentiviral vectors encoding the
heavy and light chains of anti-HER2 antibody [7] (Fig. 1A).
NSCs secreted properly assembled anti-HER2 antibody, which
speciﬁcally bound tumor cells and inhibited the proliferation
of HER2 overexpressing breast cancer cells in vitro. Further-
more, i.v.-administered NSCs delivered anti-HER2 antibody
to intramammary human breast cancer xenografts in immuno-
deﬁcient mice. Importantly, anti-HER2 antibody was not de-
tectable in the blood, whereas i.v. injected anti-HER2 anti-
body (trastuzumab) was present at high concentrations in both
tumor and blood. This suggests that NSC-mediated antibody
delivery may provide more speciﬁc tumor localization of ther-
apeutic antibodies than i.v. injection of puriﬁed antibody,
thereby potentially reducing associated toxicities to healthy
tissues.
MSCs have also been investigated as vehicles for antibody
delivery. Human MSCs have been nucleofected to express a
cell surface-bound single chain antibody (scFv) targeting the
glioma-associated epidermal growth factor receptor variant III
(EGFRvIII) [8, 9]. These scFv-expressing human MSCs local-
ized to human glioma xenografts. In addition, the presence of
scFv enhanced the retention of MSCs in the tumor paren-
chyma [9] (Fig. 1B). Exposure of glioma xenografts in the
mouse ﬂank to anti-EGFRvIII scFv-bearing MSCs resulted in
a 50% reduction in tumor size. Furthermore, in an intracranial
human glioma xenograft model, coinjection of scFv-express-
ing MSCs with glioma cells signiﬁcantly improved the sur-
vival of experimental mice. Reduced vascularization of
tumors in mice receiving coinjection of MSCs was also
observed, indicating that MSCs may have an additional thera-
peutic beneﬁt of reducing tumor angiogenesis [9].
Stem Cells As ‘‘Biological Pumps’’ for Therapeutic
Antibodies
In addition to the use of stem cells for tumor-speciﬁc anti-
body delivery, a recent study has explored the use of MSCs
as biological pumps to secrete antibody fragments into the cir-
culatory system to achieve sustained therapeutic effect.
Human MSCs expressing bispeciﬁc diabodies (single chain
antibody fragments) targeting both a-carcinoembryonic anti-
gen (a-CEA) and the T cell CD3 receptor persisted for more
than 40 days when implanted subcutaneously in immunodeﬁ-
cient mice [10] (Fig. 1C). Furthermore, secreted diabody was
detectable in mouse blood for more than 6 weeks, far exceed-
ing the serum half-life of injected puriﬁed diabody [10, 11].
MSC-secreted diabodies activated tumor-speciﬁc T cells and
reduced tumor burden in mice bearing a-CEA-expressing co-
lon cancer xenografts [10].
Considerations for Stem Cell-Mediated Antibody
Therapy
Factors that must be considered when evaluating stem cells as
a platform for antibody therapy include: (a) potential immu-
nogenicity of stem cells, (b) the optimal stem cell lineage, (c)
the preferred source of stem cells, and (d) whether this
approach is capable of achieving therapeutic concentrations of
antibody at the tumor sites.
Immunogenicity of Stem Cells. Cellular therapies, including
stem cells must overcome immunological barriers to transplan-
tation, and the potential for stem cell immunogenicity has been
the subject of controversy. Several ﬁndings suggest that stem
cells may possess some degree of ‘‘immune privilege’’ that pro-
tects against immune rejection. This unique immune status has
been reported for embryonic stem cells, NSCs, and MSCs.
However, recent studies have uncovered evidence that casts
doubt on such immune privilege. Both NSCs and MSCs under
noninﬂammatory conditions do not express MHC (major histo-
compatibility complex) class II antigens and express only low
levels of MHC class I and costimulatory molecules, such as
CD80 and CD86 [12, 13]. This makes it unlikely that such
stem cells would be directly targeted by cytolytic T cells. De-
spite low resting levels of MHC class I, NSCs are not lysed by
natural killer (NK) cells, which typically target cells lacking
MHC class I [14]. NSCs and MSCs produce anti-inﬂammatory
cytokines, including (transforming growth factor beta), which
have been shown to inhibit T cell-mediated response to stem
cells [12, 15]. Studies examining the transplantation of NSCs
and MSCs in laboratory animals have yielded differing results.
For example, mouse NSC allografts were not rejected from re-
cipient mice, unless mice were presensitized with donor mouse
splenocytes [16]. Human NSCs implanted into immunocompe-
tent mice bearing syngeneic glioma persisted for at least 2–3
weeks with only subacute, localized T cell inﬁltrate without
administration of immunosuppressive drugs (Aboody et al.,
unpublished data). Wennersten et al. reported poor NSC sur-
vival in a rat model of stroke, however, a brief regimen of the
immunosuppressive drug cyclosporin A signiﬁcantly improved
Figure 1. Strategies for stem cell-based antibody therapy of cancer. Models of potential strategies for the use of stem cells in antibody therapy.
Delivery of antibodies or antibody-like molecules directly to tumor by tumor-tropic stem cells expressing either secreted antibody (A) or cell sur-
face-bound antibody (B). Use of stem cells as ‘‘biological pumps’’ to secrete antibodies or antibody-like molecules into the bloodstream (C). All
strategies utilize unique properties of stem cells to overcome limitations of traditional antibody therapy.
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months after the cessation of immunosuppression [17]. There-
fore, stem cell survival is also inﬂuenced by the immediate
microenvironment in which they are implanted. Other strat-
egies to enhance stem cell survival after transplantation include
modiﬁcation of stem cells to increase resistance to apoptosis by
overexpressing Act [18, 19], heme oxygenase-1 expression
[20], or downregulation of MHC class I expression on stem
cells by viral stealth mechanism [21]. Together, these data sug-
gest that the hypoimmunogenic properties of NSCs and MSCs
may be insufﬁcient to prevent their rejection by an immuno-
competent host, however, immunosuppressive drugs, as well as
genetic manipulation of stem cells may allow such stem cells
to persist long enough to mediate a therapeutic effect.
Stem Cell Lineage. The ﬁrst major consideration in devel-
oping stem cells for therapeutic applications is to identify the
type of stem cell that is best suited for antibody therapy. In
addition to NSCs and MSCs, many other types of stem cells
are potentially suitable for this approach. Ultimately, the
choice of stem cell will depend on tumor tropism, efﬁciency
of antibody production and post-translational modiﬁcations,
immunogenicity, and safety.
If delivery of antibody to tumors is the desired application,
robust tumor tropism of stem cells is crucial. Although NSCs
and MSCs both display tumor tropism in vivo, their exact
mechanisms of tumor tropism do not necessarily overlap. As a
result, one of these stem cell types may demonstrate superior
tropism to a particular tumor, and therefore, prescreening of a
patient’s tumor could potentially be used to determine the type
of stem cell that would display the highest tumor tropism.
Another factor that may favor one stem cell lineage over
another is the cell’s capacity to produce effective antibodies.
We have demonstrated that NSCs can secrete intact antibody
[7], but it is possible that other types of stem cells, such as
MSCs, may be able to sustain higher levels of antibody pro-
duction. In addition to the quantity of antibody produced,
another important consideration is antibody potency. The gly-
cosylation proﬁle of an antibody signiﬁcantly affects its abil-
ity to induce effector functions such as antibody-dependent
cellular cytotoxicity and complement-dependent cytotoxicity
[2]. The optimal stem cell for antibody synthesis would pro-
duce antibodies with glycosylation proﬁles that favor
enhanced effector functions. The glycosylation of antibodies
produced by NSCs and MSCs has not yet been characterized,
but is an important subject for future study.
Finally, MSCs have been reported to have multiple safety
concerns, including contributing to tumor stroma and facilitat-
ing tumor allografts in mice [22, 23]. Furthermore, a recent
study demonstrated that bone marrow-derived MSCs can
enhance the metastatic potential of a weakly metastatic human
breast cancer cell line in mice [22]. Such safety concerns for
MSCs and other types of stem cells can potentially be miti-
gated by introducing suicide genes into the therapeutic stem
cells (e.g., HSV-Tk, E. coli cytosine deaminase, or carboxy-
lesterase) [3, 24], which may allow elimination of the stem
cells at the end of the antibody therapy. Nevertheless, these
ﬁndings demonstrate the need for careful investigation of
stem cell and tumor interactions prior to the application of
stem cell-mediated antibody therapy in human patients.
Source of Stem Cells. In addition to stem cell lineage, con-
sideration should also be given to the optimal source of stem
cells. Potential options include cells derived from autologous,
allogeneic, or xenogeneic sources. Autologous stem cells are
patient-derived and have the advantage of being nonimmuno-
genic, giving them the potential to persist longer in vivo. How-
ever, a disadvantage of autologous stem cells is that depending
on the type of stem cell desired, they may be quite difﬁcult to
isolate and expand in sufﬁcient quantities. NSCs, for example,
are signiﬁcantly harder to isolate than are bone marrow- or
adipose tissue-derived MSCs. Induced pluripotent stem cells
(iPSCs) may provide an additional source of autologous stem
cells [25], but, to our knowledge, no studies have yet investi-
gated the tumor targeting or antibody expression abilities of
iPSCs, although their potential warrants such investigations.
Allogeneic stem cells are derived from a nongenetically iden-
tical human donor, and use of allogeneic stem cells may facili-
tate the establishment of ‘‘off-the-shelf’’ stem cell lines that
would be available to a greater number of patients. The poten-
tial of stem cells to display immune privilege, as discussed
earlier, might allow allogeneic stem cells to resist immune
rejection long enough to be therapeutically effective. Xenoge-
neic cells derived from mouse or other species are another
potential cell source, but these cells are the least likely to sur-
vive immune rejection and may carry additional safety
concerns.
Stem cell-mediated therapy will require large numbers of
cells. Primary cells, however, have a limited capacity for ex
vivo propagation and expansion, largely due to differentiation
in culture, which leaves little time for genetic manipulation to
induce antibody expression. Bulk cultures of cells are also difﬁ-
cult to characterize because of inherent heterogeneity. Stem
cells immortalized with v-myc, human telomerase, SV40 large
T-antigen, or other methods provide a means to maintain and
expand clonal stem cell lines in culture indeﬁnitely. In addition,
immortalized clonal cell lines are more likely to be stable and
can be extensively characterized. However, use of oncogenes to
induce immortalization carries safety concerns that must be
adequately addressed before such cells can be used clinically.
To minimize safety concerns, immortalized cell lines can be
engineered to express suicide genes, such as cytosine deaminase
or HSV-Tk, to facilitate their elimination [3].
Concentration of Antibody at Tumor Site. A ﬁnal consider-
ation is whether stem cell-mediated antibody delivery can
generate a therapeutically effective concentration of antibody
at the tumor site. Tumor-localized antibody production is
expected to require signiﬁcantly less antibody to attain thera-
peutic concentrations at the tumor site than systemic admin-
istration of antibodies. However, whether even this concen-
tration can be achieved is not yet known. Factors inﬂuencing
the concentration of antibody at the tumor site include: (a)
the number of stem cells reaching the tumor, (b) the tumor
volume covered by stem cells, (c) the amount of antibody
produced per stem cell, (d) the duration of stem cell persist-
ence at the tumor site, and (e) antibody pharmacokinetics.
The number of stem cells reaching the tumor will depend, at
least in part, on the number of cells delivered, strength of tu-
mor tropism and the route of administration. Our data from
glioma xenograft models indicate that intracranially injected
NSCs can achieve 70%–90% tumor coverage, which may be
sufﬁcient to elicit a therapeutic effect [26]. The quantity of
antibody produced by stem cells will depend on multiple
factors, including the vectors and expression strategy used.
Stem cell fate over time must also be determined for each
disease model. The pharmacokinetic properties of the anti-
body, including tumor uptake and clearance, will be deter-
mined by the molecular size and composition of the antibody
(e.g., intact, scFv, and diabody) [11]. All of these factors
will require optimization to achieve maximal therapeutic
efﬁcacy.
2086 Stem Cell-Mediated Antibody TherapyCONCLUSION
The use of antibodies for cancer therapy has brought positive
clinical outcomes for many patients, however, some limita-
tions remain. Stem cell-mediated antibody therapy could facil-
itate sustained release of antibody speciﬁcally at the tumor
site, allowing therapeutic concentrations to be achieved with-
out the need for repeated systemic administration of high
doses of antibody. Thus, application of stem cell-mediated
antibody delivery has the potential to reduce toxicities associ-
ated with systematically administered antibodies. The success
of this approach for cancer therapy depends on the ability of
the antibody-secreting cells to reach tumor foci and to persist
long enough to achieve a therapeutic effect. The tumor-tropic
properties of stem cells and their unique ability to cross the
BBB make them promising delivery vehicles for therapeutic
antibodies. Additionally, the use of stem cells as biological
pumps may allow sustained release of therapeutic molecules
into the bloodstream. No single therapeutic modality can be
expected to be effective against all cancers, and this will
likely also be the case for stem cell-based cancer therapies.
Nevertheless, leveraging the unique properties of stem cells to
overcome current limitations has the potential to greatly
expand the power of antibody therapy to combat cancer.
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